Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Apr 20, 2024
Product Development
Triple-negative breast cancer attracts target innovation at AACR
BioCentury identifies 44 new targets presented at meeting
BioCentury | Apr 9, 2024
Discovery & Translation
AACR brings new modalities, new targets to glioblastoma
BioCentury identifies new CAR T cell designs, ADCs and other modalities, plus 37 preclinical targets for
BioCentury | Sep 28, 2022
Emerging Company Profile
Pheon: advancing ADCs with first-in-class mAb, payload platform
Start-up banks $68M series A from Brandon, Forbion and Atlas; seeks to improve on a prior attempt to design new ADC payloads
BioCentury | Jun 5, 2020
Emerging Company Profile
Epsilogen: co-opting IgE antibodies against cancer
Epsilogen leverages natural high affinity of IgE for immune cells to target solid tumors
BioCentury | Mar 29, 2018
Translation in Brief
Putting GBM in Check
How MCSP may be the next best thing for GBM CAR T therapy
Items per page:
1 - 10 of 10